Alnylam® Pharmaceuticals

Mar 20, 2025

RNAi Therapeutics Market Growth 2024-2025

Read more

Mar 17, 2025

Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space

Read more

Feb 25, 2025

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Read more

Feb 15, 2025

Alnylam CEO: New administration ushers in great season of uncertainty

Read more

Jan 23, 2025

Alnylam Pharmaceuticals receives a prestigious "Tell Award" for business investment in Switzerland

Read more

Jan 12, 2025

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Read more

Jun 28, 2023

Access Health: hATTR Amyloidosis Episode

Read more

Jan 17, 2019

Patisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Read more

Jul 04, 2018

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Read more

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Read more